

## BIOSTOCK PUBLISHES AN ARTICLE ABOUT THE KEY MILESTONE TOWARD COMMERCIALISATION - ASSAY DESIGN FREEZE

Biostock publishes an article about Prolight Diagnostics has reached high-sensitivity troponin assay design freeze, locking in the final chemical configuration and performance characteristics. This marks a transition from the development phase to manufacturing optimization, setting the stage for the upcoming clinical performance study.

Read the full article here: <https://biostock.se/en/2025/12/prolight-diagnostics-nar-assay-design-freeze-for-det-hogkansliga-troponintestet-en-avgorande-milstolpe-for-psyros/>

**For further information, please contact:**

Ulf Bladin, CEO

E-mail: [info@prolightdx.com](mailto:info@prolightdx.com)

Phone: +46 73 582 39 87

Company website: [www.prolightdx.com](http://www.prolightdx.com)

**About Us**

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

**Attachments**

**Biostock publishes an article about the key milestone toward commercialisation - assay design freeze**